featured
Efficacy and Safety of First-Line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Women With Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of First-Line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial
JAMA Oncol 2021 Jun 01;7(6)853-861, C Falandry, F Rousseau, MA Mouret-Reynier, F Tinquaut, D Lorusso, J Herrstedt, AM Savoye, L Stefani, E Bourbouloux, R Sverdlin, V D'Hondt, A Lortholary, PE Brachet, A Zannetti, E Malaurie, L Venat-Bouvet, O Trédan, L Mourey, E Pujade-Lauraine, G FreyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.